EliseAI in Talks to Raise $300M at $3.7B Valuation as a16z and Bessemer Circle Lead Role

EliseAI, the New York based company building an automated operational layer for the real estate and healthcare industries, is in advanced talks to raise 300 million dollars in a new funding round that would value the company at 3.7 billion dollars, according to a Business Insider report. Andreessen Horowitz and Bessemer Venture Partners, both existing investors in the company, are said to be discussing a lead role in the transaction, though the terms remain unsettled and neither the company nor the two firms have commented publicly on the reported talks.

If the round closes near the figures being discussed, it would represent a sharp acceleration in EliseAI's valuation trajectory. The company was valued at 2.2 billion dollars just twelve months earlier, when it closed a 250 million dollar Series E in August 2025 led by Andreessen Horowitz with participation from Bessemer, Sapphire Ventures, and Navitas Capital. That round itself had more than doubled EliseAI's valuation from the 1 billion dollar mark it reached a year before that, when a 75 million dollar Series D led by Sapphire Ventures made it one of New York's newest unicorns. A 300 million dollar raise at 3.7 billion dollars would add roughly 1.5 billion dollars in value within a single year, a pace that stands out even within a broader environment where many AI startups have struggled to raise capital at all.

EliseAI was founded in 2017 by chief executive Minna Song and chief technology officer Tony Stoyanov, who met as undergraduates at Cambridge. Song has described the idea for the company taking shape after she worked as an administrative assistant at a New York real estate firm, where she observed leasing teams repeatedly answering the same narrow set of tenant questions day after day, a pattern that convinced her the work was ripe for automation.

That original insight shaped what EliseAI eventually became: a platform that acts as an automated operational layer for the real estate industry, handling end to end tenant communication, scheduling apartment tours, and processing maintenance requests without requiring constant human intervention from leasing and property management staff. The company says its automation now touches roughly one in eight apartments across the United States, giving it substantial scale within the residential leasing market before it ever looked toward adjacent industries.

In 2022, EliseAI began extending its platform beyond housing and into healthcare, applying the same underlying approach to administrative and communication bottlenecks it had identified in real estate. The healthcare push has focused particularly on outpatient specialties such as dermatology and women's health, practices that often face rising operational costs alongside heavily manual scheduling and patient communication workflows. By integrating directly with electronic health record systems, EliseAI's healthcare product automates appointment scheduling, patient communications, and various compliance related tasks, aiming to reduce administrative burden on practice staff in much the same way its real estate product reduces workload for leasing teams.

The company's financial trajectory has closely tracked its expansion across these two verticals. EliseAI said it surpassed 100 million dollars in annualized recurring revenue in early 2025, a milestone reached largely on the strength of its real estate business before healthcare began contributing more meaningfully to overall growth. Headcount has grown accordingly, climbing from around 150 employees at the time of its Series D to more than 300 today, with staff spread across offices in New York, San Francisco, Boston, and Chicago.

Should the new round close as reported, EliseAI has said the fresh capital would go toward further scaling its core real estate automation systems while aggressively accelerating its push into healthcare, treating the sector not as a side experiment but as a second major growth pillar alongside its original housing business. Investors backing the deal appear to be betting on the same thesis that has driven EliseAI's rise so far, that specialized, vertical specific AI platforms addressing deep, industry specific operational pain points can outcompete broader general purpose AI tools within their chosen domains.

The reported talks also arrive at a moment when investor appetite for proven vertical AI companies remains strong even as funding for earlier stage or less differentiated AI startups has grown more selective. EliseAI's continued ability to raise larger rounds at steeper valuations, even as some corners of the AI funding market cool, suggests investors view the company's combination of real revenue, high customer penetration in real estate, and an expanding healthcare vertical as a durable position rather than a speculative bet on future potential. Whether the round closes exactly as described remains to be confirmed, but the scale of investor interest being reported points to continued conviction in EliseAI's approach to automating some of the most tedious, repetitive operational work inside two of the economy's largest and most essential industries.